Sangamo’s hemophilia A gene therapy giroctocogene fitelparvovec, now overseen by Pfizer, leads a pipeline of 17 wholly-owned and partnered genomic medicines—four in clinical phases; the rest, preclinical . . .
Home Neurological Disorders Alzheimers Sangamo CEO Ponders Pipeline, Reflects on Phase III ‘Proud Moment’
- Neurological Disorders
- Alzheimers
- Biogen
- Bioprocessing
- Blood Disorders
- T Cells
- CAR T-Cells
- Cell Therapy
- Drug Discovery
- GEN Edge
- Genome Editing
- Gene Therapy
- Gilead Sciences
- Novartis
- Pfizer
- Takeda
- Transplantation
- Zinc Finger Nucleases
Sangamo CEO Ponders Pipeline, Reflects on Phase III ‘Proud Moment’
Sandy Macrae discusses Pfizer-partnered hemophilia A gene therapy, and how zinc fingers could finally stop Alzheimer’s
Sangamo Therapeutics CEO Sandy Macrae, PhD, recently experienced “a very proud moment” when the Hemophilia A gene therapy it created, now overseen by Pfizer, advanced into a Phase III trial. [Sangamo Therapeutics]
